The Journal of Obstetrics and Gynecology of India

, Volume 63, Issue 5, pp 316–320

Circulating Vascular Growth Factor (VEGF) Angiopoietin-1 (Angi-1) and Soluble Tie-2 Receptor in Pregnancy Complicated with Pre-eclampsia: A Prospective Study

Original Article



Preeclampsia is a leading cause of maternal and fetal/neonatal mortality and morbidity worldwide. Although the etiology of preeclampsia (PE) is still unclear, recent studies suggest that its major phenotypes, high blood pressure and proteinuria, are due in part to the disturbed angiogenic process.

Study Design

This study included the following groups: (1) women with normal pregnancies (n = 150), (2) patients with PE (n = 88), and (3) patients who delivered small growth for date (SGA) neonate (n = 50). Maternal serum concentrations of VEGF, Angi-1, and sTie-2 were measured by a sensitive immunoassay. Non-parametric statistics were used for analysis.


The median maternal serum concentration of sVEGF and sAngi-1 was lower in normal pregnant women as compared to that in PE and SGA and the differences were statistically significant (P < 0.01). In contrast, there is a significant reduction in sTie-2 levels in PE and SGA groups as compared to that in normal pregnancy group (P < 0.01). Serum VEGF and Angi-1 were significantly higher in the late onset PE subgroup as compared to that in the early onset PE (P < 0.01), but sTie-2 was not significantly different in the 2 subgroups (P > 0.05). Serum VEGF, sAngi-1, and sTie-2 were significantly higher and Tie-2 was significantly lower in the severe PE subgroup as compared to that of the milder PE subgroup (P < 0.01 for all).


Patients with PE and those with SGA fetuses have lower median serum concentrations of sTie-2 and higher sVEGF and sAngi-1 than women with normal pregnancies. These findings lend support to the hypothesis that circulating angiogenic proteins may have an important biologic role in PE.


Preeclampsia Angiopoietin-1 VEGF Tie-2 


  1. 1.
    Lapaire O, Shennan A, Stepan H. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol. 2010;151(2):122–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Leinonen E, Wathén KA, Alfthan H, et al. Maternal serum angiopoietin-1 and -2 and tie-2 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab. 2010;95(1):126–33.PubMedCrossRefGoogle Scholar
  3. 3.
    Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439–42.PubMedCrossRefGoogle Scholar
  4. 4.
    Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376:70–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Geva E, Jaffe RB. Role of angiopoietins in reproductive tract angiogenesis. Obstet Gynecol Surv. 2000;55:511–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Suri C, McClain J, Thurston G, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science. 1998;282:468–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Dumont DJ, Gradwohl G, Fong GH, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 1994;8:1897–909.PubMedCrossRefGoogle Scholar
  10. 10.
    Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389–95.PubMedCrossRefGoogle Scholar
  12. 12.
    Witzenbichler B, Maisonpierre PC, Jones P, et al. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie-2. J Biol Chem. 1998;273:18514–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Wulff C, Wilson H, Dickson SE, et al. Hemochorial placentation in the primate: expression of vascular endothelial growth factor, angiopoietins, and their receptors throughout pregnancy. Biol Reprod. 2002;66:802–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Babischkin JS, Suresch DL, Pepe GJ, et al. Differential expression of placental villous angiopoietin-1 and -2 during early mid and late baboon pregnancy. Placenta. 2007;28:212–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Janota J, Pomyje J, Toth D, et al. Expression of angiopoietic factors in normal and type-I diabetes human placenta: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2003;111:153–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of preeclampsia. J Matern Fetal Neonatal Med. 2005;17:3–18.PubMedCrossRefGoogle Scholar
  17. 17.
    Polliotti BM, Fry AG, Saller DN, et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol. 2003;101:1266–74.PubMedCrossRefGoogle Scholar
  18. 18.
    Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.PubMedCrossRefGoogle Scholar
  19. 19.
    Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005;46:1077–85.PubMedCrossRefGoogle Scholar
  20. 20.
    Sibai BM, Ewell M, Levine RJ, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol. 1997;177:1003–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol. 1996;87:163–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med. 2008;59:61–78.PubMedCrossRefGoogle Scholar
  23. 23.
    Sung JF, Fan X, Dhal S, et al. Decreased circulating soluble Tie-2 levels in preeclampsia may result from inhibition of vascular endothelial growth factor (VEGF) signaling. J Clin Endocrinol Metab. 2011;96(7):E1148–52.PubMedCrossRefGoogle Scholar
  24. 24.
    Nadar SK, Karalis I, Al Yemeni E, et al. Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb Haemost. 2005;94:1071–6.PubMedGoogle Scholar
  25. 25.
    Gotsch F, Romero R, Kusanovic JP, et al. Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2. J Matern Fetal Neonatal Med. 2008;21(6):389–402.PubMedCrossRefGoogle Scholar
  26. 26.
    Hirokoshi K, Maeshima Y, Kobayashi K, et al. Increase of serum angiopoietin-2 during pregnancy is suppressed in women with preeclampsia. Am J Hypertens. 2005;18:1181–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Findley MC, Cudmore JM, Ahmed A, et al. VEGF Induces Tie-2 shedding via a phosphoinositide 3-kinase/Akt–dependent pathway to modulate Tie-2 signaling. Arterioscler Thromb Vasc Biol. 2007;27:2619–26.PubMedCrossRefGoogle Scholar
  28. 28.
    Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004;190:1541–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Dunk C, Shams M, Nijjar S, et al. Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. Am J Pathol. 2000;156(6):2185–99.PubMedCrossRefGoogle Scholar
  31. 31.
    Hagen AS, Orbus RJ, Wilkening RB, et al. Placental expression of angiopoietin-1, angiopoietin-2 and Tie-2 during placental development in an ovine model of placental insufficiency-fetal growth restriction. Pediatr Res. 2005;58(6):1228–32.PubMedCrossRefGoogle Scholar

Copyright information

© Federation of Obstetric & Gynecological Societies of India 2013

Authors and Affiliations

  1. 1.Hematology Unit, Clinical Pathology DepartmentMansoura Faculty of MedicineMansouraEgypt
  2. 2.Obstetric and Gynacology DepartmentMansoura Faculty of MedicineMansouraEgypt

Personalised recommendations